CPG
AUTL icon

Cornerstone Planning Group’s Autolus Therapeutics AUTL Stock Holding History

Cornerstone Planning Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$226 – 1568
2024
Q4 		$226 Hold
100
– – ﹤0.01% 1318
2024
Q3 		$434 Hold
100
– – ﹤0.01% 1117
2024
Q2 		$425 Hold
100
– – ﹤0.01% 1099
2024
Q1 		$419 Hold
100
– – ﹤0.01% 968
2023
Q4 		$644 Hold
100
– – ﹤0.01% 758
2023
Q3 		$233 Buy
+100
New +$285 ﹤0.01% 1010

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cornerstone Planning Group's AUTL Position: Q1 2025 in Review

Cornerstone Planning Group sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 100 shares — an estimated $226 sold.

Cornerstone Planning Group first reported a position in AUTL in Q3 2023 and held it in 6 quarters. The position peaked at $644 in Q4 2023. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Cornerstone Planning Group reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cornerstone Planning Group sold 100 Autolus Therapeutics shares in Q1 2025, an estimated $226.
  • Cornerstone Planning Group first reported a position in Autolus Therapeutics in Q3 2023 and held it in 6 quarters.
  • Cornerstone Planning Group's Autolus Therapeutics position peaked at $644 in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Cornerstone Planning Group's 13F filing for Q1 2025, filed 30 Apr 2025.